| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
The identification of many tumor-associated epitopes as nonmutated "self" Ags led to the hypothesis that the induction of large numbers of self/tumor Ag-specific T cells would be prevented because of central and peripheral tolerance. We report in this study on vaccination efforts in 95 HLA-A*0201 patients at high risk for recurrence of malignant melanoma who received prolonged immunization with the "anchor-modified" synthetic peptide, gp100209–217(210M). Vaccination using this altered peptide immunogen was highly effective at inducing large numbers of self/tumor-Ag reactive T cells in virtually every patient tested, with levels as high as 42% of all CD8+ T cells assessed by tetramer analysis. From 1 to 10% of all CD8+ cells were tumor-Ag reactive in 44% of patients and levels >10% were generated in 17% of patients. These studies were substantiated using the ELISPOT assay and a bulk cytokine release assay. Although our data regarding "tumor escape" were inconclusive, some patients had growing tumors that expressed Ag and HLA-A*0201 in the presence of high levels of antitumor T cells. There was no difference in the levels of antitumor Ag-specific T cells in patients who recurred compared with those that remained disease-free. Thus, the mere presence of profoundly expanded numbers of vaccine-induced, self/tumor Ag-specific T cells cannot by themselves be used as a "surrogate marker" for vaccine efficacy. Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  J. Fourcade, P. Kudela, Z. Sun, H. Shen, S. R. Land, D. Lenzner, P. Guillaume, I. F. Luescher, C. Sander, S. Ferrone, et al. PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients J. Immunol., May 1, 2009; 182(9): 5240 - 5249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Kilinc, T. Gu, J. L. Harden, L. P. Virtuoso, and N. K. Egilmez Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity J. Immunol., April 1, 2009; 182(7): 4217 - 4225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Harlin, Y. Meng, A. C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T. F. Gajewski Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment Cancer Res., April 1, 2009; 69(7): 3077 - 3085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Walker, W. Miller, D. Haley, K. Floyd, B. Curti, and W. J. Urba Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood Clin. Cancer Res., April 1, 2009; 15(7): 2541 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Nevala, C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson, S. N. Markovic, and for the Melanoma Study Group of the Mayo Clinic Ca Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma Clin. Cancer Res., March 15, 2009; 15(6): 1931 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Mailloux and M. R. I. Young NK-Dependent Increases in CCL22 Secretion Selectively Recruits Regulatory T Cells to the Tumor Microenvironment J. Immunol., March 1, 2009; 182(5): 2753 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al. Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy Cancer Res., December 15, 2008; 68(24): 10247 - 10256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma Cancer Res., December 1, 2008; 68(23): 9884 - 9891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rosenberg Overcoming obstacles to the effective immunotherapy of human cancer PNAS, September 2, 2008; 105(35): 12643 - 12644. [Full Text] [PDF]
|
|
|
|
|
|
S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells J. Immunol., September 1, 2008; 181(5): 3099 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Walker, D. Haley, U. Petrausch, K. Floyd, W. Miller, N. Sanjuan, G. Alvord, B. A. Fox, and W. J. Urba Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization Clin. Cancer Res., August 15, 2008; 14(16): 5270 - 5283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Palmer, C.-C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, et al. From the Cover: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity PNAS, June 10, 2008; 105(23): 8061 - 8066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Epardaud, K. G. Elpek, M. P. Rubinstein, A.-r. Yonekura, A. Bellemare-Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley Interleukin-15/Interleukin-15R{alpha} Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells Cancer Res., April 15, 2008; 68(8): 2972 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors Cancer Res., April 1, 2008; 68(7): 2436 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. J. Wong, R. Bos, and L. A. Sherman Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells J. Immunol., March 1, 2008; 180(5): 3122 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases J. Immunol., January 1, 2008; 180(1): 130 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Kochenderfer and R. E. Gress A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies Experimental Biology and Medicine, October 1, 2007; 232(9): 1130 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al. Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo J. Immunol., October 1, 2007; 179(7): 4919 - 4928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ko, W. Luo, L. Peng, X. Wang, and S. Ferrone Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity Cancer Res., August 15, 2007; 67(16): 7875 - 7884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weishaupt, K. N. Munoz, E. Buzney, T. S. Kupper, and R. C. Fuhlbrigge T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma Clin. Cancer Res., May 1, 2007; 13(9): 2549 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Powell Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion J. Immunol., November 1, 2006; 177(9): 6527 - 6539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nelson and R. Ganss Tumor growth or regression: powered by inflammation J. Leukoc. Biol., October 1, 2006; 80(4): 685 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tormo, A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, J. Wenzel, and T. Tuting Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. Cancer Res., May 15, 2006; 66(10): 5427 - 5435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Manjili, M. Kmieciak, and J. Keeler Comment on "Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma". J. Immunol., April 15, 2006; 176(8): 4511 - 4511. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rosenberg and N. P. Restifo Response to Comment on "Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma". J. Immunol., April 15, 2006; 176(8): 4511 - 4512. [Full Text] [PDF]
|
|
|
|
|
|
B. E. Loveland, A. Zhao, S. White, H. Gan, K. Hamilton, P.-X. Xing, G. A. Pietersz, V. Apostolopoulos, H. Vaughan, V. Karanikas, et al. Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma Clin. Cancer Res., February 1, 2006; 12(3): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
